194 related articles for article (PubMed ID: 16572306)
21. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
van Aswegen A; Roodt A; Marais J; Botha JM; Naudé H; Lötter MG; Goedhals L; Doman MJ; Otto AC
Nucl Med Commun; 1997 Jun; 18(6):582-8. PubMed ID: 9259533
[TBL] [Abstract][Full Text] [Related]
22. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
23. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
[TBL] [Abstract][Full Text] [Related]
24. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Liepe K; Kropp J; Runge R; Kotzerke J
Br J Cancer; 2003 Aug; 89(4):625-9. PubMed ID: 12915868
[TBL] [Abstract][Full Text] [Related]
26. The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer.
Binnie D; Divoli A; McCready VR; Dearnaley D; Flux G
Cancer Biother Radiopharm; 2005 Apr; 20(2):189-94. PubMed ID: 15869454
[TBL] [Abstract][Full Text] [Related]
27. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Liepe K; Kropp J; Hliscs R; Franke WG
Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
[TBL] [Abstract][Full Text] [Related]
28. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
29. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
32. Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results.
Schoeneich G; Palmedo H; Dierke-Dzierzon C; Müller SC; Biersack HJ
Scand J Urol Nephrol; 1997 Oct; 31(5):445-8. PubMed ID: 9406304
[TBL] [Abstract][Full Text] [Related]
33. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma.
Syed R; Bomanji J; Nagabhushan N; Kayani I; Groves A; Waddington W; Cassoni A; Ell PJ
J Nucl Med; 2006 Dec; 47(12):1927-35. PubMed ID: 17138735
[TBL] [Abstract][Full Text] [Related]
34. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases.
Sciuto R; Tofani A; Festa A; Giannarelli D; Pasqualoni R; Maini CL
J Nucl Med; 2000 Apr; 41(4):647-54. PubMed ID: 10768566
[TBL] [Abstract][Full Text] [Related]
35. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
[TBL] [Abstract][Full Text] [Related]
36. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Biersack HJ; Palmedo H; Andris A; Rogenhofer S; Knapp FF; Guhlke S; Ezziddin S; Bucerius J; von Mallek D
J Nucl Med; 2011 Nov; 52(11):1721-6. PubMed ID: 21976530
[TBL] [Abstract][Full Text] [Related]
37. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
Wiesmann A; Einsele H; Kanz L; Dohmen BM
Bone Marrow Transplant; 2005 Jul; 36(1):89-90. PubMed ID: 15895113
[No Abstract] [Full Text] [Related]
38. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
Ogawa K; Mukai T; Arano Y; Ono M; Hanaoka H; Ishino S; Hashimoto K; Nishimura H; Saji H
Bioconjug Chem; 2005; 16(4):751-7. PubMed ID: 16029015
[TBL] [Abstract][Full Text] [Related]
39. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A
Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
[TBL] [Abstract][Full Text] [Related]
40. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Cancer Biother Radiopharm; 2009 Oct; 24(5):543-50. PubMed ID: 19877884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
